# Trade Mark Journal No.2026/018 1 May 2026

## WO0000001913184 (1,5,42,44)

Office of origin: Switzerland

Date of International Registration:14 January 2026
Date of designation in the UK: 14 January 2026

International priority date claimed: 8 October 2025 (Switzerland) (837715)

Class 1
  Biological preparations other than for medical or veterinary use; stem cells other than for medical or veterinary use; non-stem cells other than for medical or veterinary use; cell culture reagents, matrices and media other than for medical or veterinary use; cell lines for scientific use; molecular genetics reagents, plasmids, and vectors for scientific use.
Class 5
  Pharmaceutical products, medical and veterinary preparations; pharmaceutical preparations for activating cellular functions; medical preparations for the treatment of the brain and nervous system, including neurodegenerative diseases and movement disorders; medical preparations for the treatment of Parkinson's disease; biotechnological preparations for medical use; biotechnological preparations for gene or cell therapy; cells for medical use; living cells and living tissues for medical use; theranostic therapeutic cells; surgical implants consisting of living tissues and cells; chemical or biological reagents and culture media for medical use; diagnostic agents for medical use; diagnostic kits for medical use.
Class 42
  Scientific and technological services as well as research and design services relating thereto; scientific and technological services in the field of cell therapy; scientific and technological services in the field of genetic engineering; genetic engineering services; scientific and technological services in the field of brain and nervous system conditions; scientific and technological services in the field of neuroregenerative medicine and neurobiology; synthetic biology research and development; design, especially assisted by artificial intelligence, of therapeutic proteins; development and validation of production processes for cell therapy agents for quality or standards certification; design and development of tests to identify, quantify, analyze, and validate biomarkers in the field of brain or nervous system degeneration; bioinformatics-based medical data analysis services in the field of brain or nervous system degeneration.
Class 44
  Medical services; regenerative medicine services; cultured cell bank services for medical transplantation; medical treatment services by means of cultured cells; medical treatment services by means of cell therapy; preparation, expansion and characterization of cells for therapeutic purposes; clinical advice on cell therapy; genetic analysis services for medical use.

AZURECELL SA

Representative: reuteler & cie SA, Chemin de la Vuarpillière 29, CH-1260 Nyon, SWITZERLAND